Literature DB >> 26041500

Safe limits of contrast vary with hydration volume for prevention of contrast-induced nephropathy after coronary angiography among patients with a relatively low risk of contrast-induced nephropathy.

Yong Liu1, Ji-Yan Chen2, Ning Tan2, Ying-Ling Zhou1, Dan-Qing Yu1, Zhu-Jun Chen1, Yi-Ting He1, Yuan-Hui Liu1, Jian-Fang Luo1, Wen-Hui Huang1, Guang Li1, Peng-Cheng He1, Jun-Qing Yang1, Nian-Jin Xie1, Xiao-Qi Liu1, Da-Hao Yang1, Shui-Jin Huang1, Hua-Long Li1, Peng Ran1, Chong-Yang Duan1, Ping-Yan Chen2.   

Abstract

BACKGROUND: Few studies have investigated the safe limits of contrast to prevent contrast-induced nephropathy (CIN) based on hydration data. We aimed to investigate the relative safe maximum contrast volume adjusted for hydration volume in a population with a relatively low risk of CIN. METHODS AND
RESULTS: The ratios of contrast volume-to-creatinine clearance (V/CrCl) and hydration volume to body weight (HV/W) were determined in patients undergoing cardiac catheterization. Receiver-operator characteristic curve analysis based on the maximum Youden index was used to identify the optimal cutoff for V/CrCl in all patients and in HV/W subgroups. Eighty-six of 3273 (2.6%) patients with mean CrCl 71.89±27.02 mL/min developed CIN. Receiver-operator characteristic curve analysis indicated that a V/CrCl ratio of 2.44 was a fair discriminator for CIN in all patients (sensitivity, 73.3%; specificity, 70.4%). After adjustment for other confounders, V/CrCl >2.44 continued to be significantly associated with CIN (adjusted odds ratio, 4.12; P<0.001) and the risk of death (adjusted hazard ratio, 2.62; P<0.001). The mean HV/W was 12.18±7.40. We divided the patients into 2 groups (HV/W ≤12 and >12 mL/kg). The best cutoff value for V/CrCl was 1.87 (sensitivity, 67.9%; specificity, 64.4%; adjusted odds ratio, 3.24; P=0.011) in the insufficient hydration subgroup (HV/W, ≤12 mL/kg; CIN, 1.32%) and 2.93 (sensitivity, 69.0%; specificity, 65.0%; adjusted odds ratio, 3.04; P=0.004) in the sufficient hydration subgroup (HV/W, >12 mL/kg; CIN, 5.00%).
CONCLUSIONS: The V/CrCl ratio adjusted for HV/W may be a more reliable predictor of CIN and even long-term outcomes after cardiac catheterization. We also found a higher best cutoff value for V/CrCl to predict CIN in patients with a relatively sufficient hydration status, which may be beneficial during decision-making about contrast dose limits in relatively low-risk patients with different hydration statuses.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  diabetes mellitus; glomerular filtration rate; percutaneous coronary intervention

Mesh:

Substances:

Year:  2015        PMID: 26041500     DOI: 10.1161/CIRCINTERVENTIONS.114.001859

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  19 in total

1.  A Simple Modified Framingham Scoring System to Predict Obstructive Coronary Artery Disease.

Authors:  Yong Liu; Qiang Li; Shiqun Chen; Xia Wang; Yingling Zhou; Ning Tan; Jiyan Chen
Journal:  J Cardiovasc Transl Res       Date:  2018-10-12       Impact factor: 4.132

Review 2.  Complex PCI procedures: challenges for the interventional cardiologist.

Authors:  Nikos Werner; Georg Nickenig; Jan-Malte Sinning
Journal:  Clin Res Cardiol       Date:  2018-07-05       Impact factor: 5.460

3.  Simple pre-procedure risk stratification tool for contrast-induced nephropathy.

Authors:  Zhonghan Ni; Yan Liang; Nianjin Xie; Jin Liu; Guoli Sun; Shiqun Chen; Jianfeng Ye; Yibo He; Wei Guo; Ning Tan; Jiyan Chen; Yong Liu; Zhujun Chen; Shouhong Wang
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

4.  Excessively High Hydration Volume May Not Be Associated With Decreased Risk of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention in Patients With Renal Insufficiency.

Authors:  Yong Liu; Hualong Li; Shiqun Chen; Jiyan Chen; Ning Tan; Yingling Zhou; Yuanhui Liu; Piao Ye; Peng Ran; Chongyang Duan; Pingyan Chen
Journal:  J Am Heart Assoc       Date:  2016-05-27       Impact factor: 5.501

5.  Percutaneous coronary intervention for chronic total occlusion improved prognosis in patients with renal insufficiency at high risk of contrast-induced nephropathy.

Authors:  Yong Liu; Yuanhui Liu; Hualong Li; Yingling Zhou; Wei Guo; Chongyang Duan; Shiqun Chen; Pingyan Chen; Ning Tan; Jiyan Chen
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

6.  Optimal hydration volume among high-risk patients with advanced congestive heart failure undergoing coronary angiography.

Authors:  Shi-Qun Chen; Yong Liu; Wei Jie Bei; Ying Wang; Chong-Yang Duan; Deng-Xuan Wu; Kun Wang; Ping Yan Chen; Ji-Yan Chen; Ning Tan; Li-Wen Li
Journal:  Oncotarget       Date:  2018-05-04

7.  Relationship Between the Urine Flow Rate and Risk of Contrast-Induced Nephropathy After Emergent Percutaneous Coronary Intervention.

Authors:  Yong Liu; Lixia Lin; Yun Li; Hualong Li; Deng-Xuan Wu; Jian-Bin Zhao; Dan Lian; Yingling Zhou; Yuanhui Liu; Piao Ye; Peng Ran; Chongyang Duan; Shiqun Chen; Pingyan Chen; Ying Xian; Jiyan Chen; Ning Tan
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Predicting contrast-induced nephropathy after CT pulmonary angiography in the critically ill: a retrospective cohort study.

Authors:  Kwok M Ho; Yusrah Harahsheh
Journal:  J Intensive Care       Date:  2018-01-19

9.  A simple prediction model to estimate obstructive coronary artery disease.

Authors:  Shiqun Chen; Yong Liu; Sheikh Mohammed Shariful Islam; Hua Yao; Yingling Zhou; Ji-Yan Chen; Qiang Li
Journal:  BMC Cardiovasc Disord       Date:  2018-01-16       Impact factor: 2.298

10.  Could late measurement of serum creatinine be missed for patients without early increase in serum creatinine following coronary angiography?

Authors:  Yong Liu; Chong-Yang Duan; Kun Wang; Wei-Jie Bei; Xiao-Sheng Guo; Hua-Long Li; Ying Wang; Shi-Qun Chen; Ying Xian; Ping-Yan Chen; Qing-Shan Geng; Ning Tan; Ji-Yan Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.